The changing paradigm of atopic dermatitis therapy

Sheila F. Friedlander, Eric Simpson, Alan D. Irvine, Lawrence F. Eichenfield

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The pathophysiology of atopic dermatitis (AD) is complex, and future treatment options will likely be incorporated in a multimodal approach to management. The new, directed therapies that have been developed will likely be used in conjunction with concomitant continuous or intermittent use of standard therapies; the goal is to optimize therapeutic outcomes while minimizing adverse impacts on safety and cost. Current data regarding disease course and expression throughout life suggest that treatment strategies also will need to be adjusted as a patient grows. Research also indicates that interventions begun in infancy-such as the use of emollients-may mitigate or prevent AD signs and symptoms in children at high risk for the disease.

Original languageEnglish (US)
Pages (from-to)97S-99S
JournalSeminars in Cutaneous Medicine and Surgery
Volume35
DOIs
StatePublished - Jun 1 2016

Fingerprint

Atopic Dermatitis
Emollients
Therapeutics
Signs and Symptoms
Safety
Costs and Cost Analysis
Research

Keywords

  • Atopic dermatitis
  • Petrolatum
  • Pimecrolimus
  • Tacrolimus
  • Topical calcineurin inhibitors
  • Topical immunomodulators

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)
  • Dermatology

Cite this

The changing paradigm of atopic dermatitis therapy. / Friedlander, Sheila F.; Simpson, Eric; Irvine, Alan D.; Eichenfield, Lawrence F.

In: Seminars in Cutaneous Medicine and Surgery, Vol. 35, 01.06.2016, p. 97S-99S.

Research output: Contribution to journalArticle

Friedlander, Sheila F. ; Simpson, Eric ; Irvine, Alan D. ; Eichenfield, Lawrence F. / The changing paradigm of atopic dermatitis therapy. In: Seminars in Cutaneous Medicine and Surgery. 2016 ; Vol. 35. pp. 97S-99S.
@article{e94a02d1e0a4427b9ce8c6645e7e6356,
title = "The changing paradigm of atopic dermatitis therapy",
abstract = "The pathophysiology of atopic dermatitis (AD) is complex, and future treatment options will likely be incorporated in a multimodal approach to management. The new, directed therapies that have been developed will likely be used in conjunction with concomitant continuous or intermittent use of standard therapies; the goal is to optimize therapeutic outcomes while minimizing adverse impacts on safety and cost. Current data regarding disease course and expression throughout life suggest that treatment strategies also will need to be adjusted as a patient grows. Research also indicates that interventions begun in infancy-such as the use of emollients-may mitigate or prevent AD signs and symptoms in children at high risk for the disease.",
keywords = "Atopic dermatitis, Petrolatum, Pimecrolimus, Tacrolimus, Topical calcineurin inhibitors, Topical immunomodulators",
author = "Friedlander, {Sheila F.} and Eric Simpson and Irvine, {Alan D.} and Eichenfield, {Lawrence F.}",
year = "2016",
month = "6",
day = "1",
doi = "10.12788/j.sder.2016.044",
language = "English (US)",
volume = "35",
pages = "97S--99S",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - The changing paradigm of atopic dermatitis therapy

AU - Friedlander, Sheila F.

AU - Simpson, Eric

AU - Irvine, Alan D.

AU - Eichenfield, Lawrence F.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The pathophysiology of atopic dermatitis (AD) is complex, and future treatment options will likely be incorporated in a multimodal approach to management. The new, directed therapies that have been developed will likely be used in conjunction with concomitant continuous or intermittent use of standard therapies; the goal is to optimize therapeutic outcomes while minimizing adverse impacts on safety and cost. Current data regarding disease course and expression throughout life suggest that treatment strategies also will need to be adjusted as a patient grows. Research also indicates that interventions begun in infancy-such as the use of emollients-may mitigate or prevent AD signs and symptoms in children at high risk for the disease.

AB - The pathophysiology of atopic dermatitis (AD) is complex, and future treatment options will likely be incorporated in a multimodal approach to management. The new, directed therapies that have been developed will likely be used in conjunction with concomitant continuous or intermittent use of standard therapies; the goal is to optimize therapeutic outcomes while minimizing adverse impacts on safety and cost. Current data regarding disease course and expression throughout life suggest that treatment strategies also will need to be adjusted as a patient grows. Research also indicates that interventions begun in infancy-such as the use of emollients-may mitigate or prevent AD signs and symptoms in children at high risk for the disease.

KW - Atopic dermatitis

KW - Petrolatum

KW - Pimecrolimus

KW - Tacrolimus

KW - Topical calcineurin inhibitors

KW - Topical immunomodulators

UR - http://www.scopus.com/inward/record.url?scp=85020318295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020318295&partnerID=8YFLogxK

U2 - 10.12788/j.sder.2016.044

DO - 10.12788/j.sder.2016.044

M3 - Article

VL - 35

SP - 97S-99S

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

ER -